EORTC and Pierre Fabre partner to address treatment gap for stage 2 melanoma patients

(European Organisation for Research and Treatment of Cancer) European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma. The partnership includes the planning, design and execution of a large Phase 3 study investigating the use of BRAF and MEK targeted therapies to reduce the risk of relapse in this patient population, currently under approval with authorities.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news